Podcasts about nbs

Ever feel like you're stuck in the "messy middle" and on the operations "hamster wheel" in your practice? If so, this one's for you. Mandy Brown joins me to talk about operational efficiency and what it really takes to run a well-functioning optometry practice.   We discuss the challenges practice owners face with delegation, the importance of hiring the right people, and developing an operational mindset that supports long-term success. Mandy also shares how virtual assistants can play a meaningful role in freeing up time, improving focus, and helping owners work more intentionally on their business rather than getting stuck in the day-to-day. We wrap up the episode with Mandy providing a very insightful NBS for listeners to consider.   Resources: Connect with Mandy on LinkedIn How one owner left his practice for 30 days—and why more owners should consider it Book a Triage call with Adam Download the Practice Owner's Financial Toolkit 20/20 Money Ultimate Financial Success Masterclass OD Mastermind Interest Form Check out Adam's new book: How to Buy an Optometry Practice   ————————————————————————————— Please rate and subscribe to 20/20 Money on these platforms Apple Podcasts Spotify ————————————————————————————— For past episodes of 20/20 Money with full companion show notes, please check out our episode archive here!   The Optometry Success Podcast  Subscribe on Apple Podcasts: https://bit.ly/4tttng6 Subscribe on Spotify: https://bit.ly/4tuf0YM 

1. Slovensko má (zatiaľ) zásoby ropy a aj alternatívy dodávok 2. Zle nastavená konsolidácia dusí ekonomiku: Slovensko čaká najslabšia päťročnica 3. NBS je v bizarnom personálnom vákuu: guvernér po mandáte, viceguvernér bez agendy 

The eyes of the racing world turn to Southwell on Friday night as Constitution Hill makes his Flat racing debut in the SBK Road To Cheltenham Novice Stakes. Tom Collins and Ross Millar are on hand to preview the big race before TC catches up with Sam Twiston-Davies to get the insight on his rides for Saturday.Kempton's Dovecote Novices' Hurdle and Ladbrokes Trophy Handicap Chase are in the spotlight before the panel move on to their NAP & NBs.Let us know if you think Constitution Hill wins and whether we will see him at Cheltenham below? Hosted on Acast. See acast.com/privacy for more information.

After a successful weekend for both Ross and TC at Newbury last time out, the SBK Betting Podcast returns to preview all the action from Ascot and Haydock.Sam Twiston-Davies also gives us the inside scoop on his return to ride for Paul Nicholls before discussing his chances this weekend.TC and Ross give their best bets for the Reynoldstown Chase and Ascot Chase before travelling north to give their tips for the Grand National Trial at Haydock.As always, NAPs & NBs round off this week's podcast.Got a selection? Drop it in the comments. Hosted on Acast. See acast.com/privacy for more information.

Hostia: Ivan Šramko (bývalý guvernér NBS, veľvyslanec SR pri OECD v Paríži) a Ľuboš Pavelka (erudovaný a rešpektovaný odborník a špecialista na devízy a bankovníctvo). | Národná zlatá rezerva štátu symbolizuje štátnu suverenitu a aj ekonomickú nezávislosť. Je preto optimálne ju mať uloženú mimo územia Slovenska a Európskej únie? Je pre štát vhodné zväčšovať štátne zlaté rezervy alebo radšej investovať financie iným spôsobom (do dlhopisov či digitálnych mien)? Obzvlášť, pokiaľ sme súčasťou eurozóny? Vníma štát zlato ako investíciu do istoty a budúcnosti, na ktorej sa dá aj zarobiť - a podobne ako iné krajiny sveta ho nakupuje a zväčšuje jeho zásoby, alebo nie? Má Slovensko na presun zo Spojeného kráľovstva Veľkej Británie a Severného Írska na Slovensko - v čase konsolidácie dostatok voľných finančných zdrojov? Máme dostatočne bezpečné priestory na jeho uskladnenie? | Vrátia sa slovenské zlaté rezervy na Slovensko? | Moderuje: Matej Baránek; | Diskusiu Z prvej ruky pripravuje Slovenský rozhlas, Rádio Slovensko, SRo1. Vysielame každý pracovný deň o 12:30 v Rádiu Slovensko.

Welcome back to Season 9 of the Recovering Perfectionist Podcast!In this episode, Christine chats with our newest Dance Wellness Community Ambassador and first one to represent Ballet, Ian Parsons. Ian is an internationally recognized ballet educator, choreographer, and former professional dancer whose career spans elite classical performance, commercial theatre, and advanced professional training. A double graduate of Canada's National Ballet School, he completed both the Professional Ballet Program and the highly selective Teacher Training Program for Former Professional Dancers, earning the Betty Oliphant Award for Excellence in Teaching.As a performer, Ian danced with The National Ballet of Canada and Les Ballets de Monte-Carlo, working with choreographers including James Kudelka, John Neumeier, Jiří Kylián, and Jean-Christophe Maillot. His career also includes appearances in the feature film adaptation of Les Misérables, the Olivier Award–nominated West End revival of Cabaret, and the UK and European tour of Cats, with the distinction of performing at the Olivier Awards at the Royal Opera House.Following his performing career, Ian developed an extensive teaching and leadership practice across Canada, the UK, and the United States. He joined the artistic faculty of Canada's National Ballet School, where he taught across all levels of the Professional Ballet Program, from foundational training through to stage-ready repertoire. During his tenure, he created the school's formalized pas de deux curriculum and served as Manager of the International Exchange Program, overseeing international placements for more than 100 students annually. His students have gone on to perform with companies including The Royal Ballet, American Ballet Theatre, Dutch National Ballet, Boston Ballet, Stuttgart Ballet, Houston Ballet, Tulsa Ballet, The Washington Ballet, Miami City Ballet, and The National Ballet of Canada, among many others.In addition to his work at NBS, Ian has taught and choreographed for professional training programs and institutions in Canada and the UK, including Performers College, The School of Ballet Theatre UK, Chantry School, Canada's Ballet Jörgen, and the Maritime Conservatory of Performing Arts, with choreography presented by Youth America Grand Prix and conservatory-level programs across North America and Europe.Ian's teaching philosophy is grounded in classical rigor, musical clarity, and long-term dancer development. Shaped by years of institutional teaching, curriculum design, and mentorship, his work centers on maintaining uncompromising technical standards while supporting dancers as whole artists, with an emphasis on sustainability, agency, and artistic longevity. Ian is currently the Artistic Director of Ballet Theatre of Phoenix and Convergence Ballet, and is based in Phoenix, Arizona.DANCE WELLNESS COMMUNITY:Join us in the INNER CIRCLE:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://dancewellnesscommunity.com⁠⁠⁠⁠⁠⁠CONNECT WITH IAN:https://www.instagram.com/ianparsonsballet/CHRISTINE BAR NOEL:All The Things! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://beacons.ai/christinebarnoel⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/recoveringperfectionistpodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/dancewellnesscommunity

This week on the SBK Betting Podcast, Tom Collins, Ross Millar, and Sam Twiston-Davies analyse the Denman Chase, Game Spirit Chase, and the William Hill Hurdle and look at what impact this weekend's racing could have on the Cheltenham Festival coming March.Sam also gives his insight into his three rides at Newbury this weekend.As always, the episode wraps up with the team's NAPs & NBs, giving their strongest selections for the weekend.Got a fancy of your own? Drop your predictions in the comments Hosted on Acast. See acast.com/privacy for more information.

This week on the SBK Betting Podcast, Tom Collins, Ross Millar, and Sam Twiston-Davies break down the biggest weekend races. The panel analyse the Scottish Champion Chase, Scilly Isles Novices' Chase, and the Irish Gold Cup. Will Galopin Des Champs make it four in a row?They also share a few horses to keep an eye on at the Dublin Racing Festival on Sunday. Will there be any Cheltenham Festival clues?As always, the episode wraps up with the team's NAPs & NBs.Got a fancy of your own? Drop your selections in the comments Hosted on Acast. See acast.com/privacy for more information.

Vládna konsolidácia škrtí náš ekonomický rast. Problémom sú neadresné vládne výdavky, napr. plošné 13. dôchodky či sociálne benefity i pre tých, ktorí ich vôbec nepotrebujú, tvrdí exguvernér NBS Šramko. Prečo by bol odchod z EÚ pre Slovensko katastrofou a hrozí nám reálny bankrot štátu?Prvý január 2009, deň, v ktorom Slovensko prijalo novú menu a pripojilo sa tak k elitnému euroklubu. Zavedenie eura sprevádzali polemiky ohľadom konverzného kurzu, ale dôvodmi pochybností boli aj možné menové špekulácie, ktoré otvorila návšteva vtedajšieho ministra financií na jachte spolumajiteľa jednej z finančných skupín, za ktorú si vyslúžil od premiéra “žltú kartu.” Jedným z otcov Eura na Slovensku bol aj vtedajší guvernér Národnej banky Slovenska Ivan Šramko. Ako dnes jeden z otcov slovenského eura hodnotí stav slovenskej ekonomiky a aké odporúčanie by dal našej vláde pri zatiaľ neúspešnej konsolidácií verejných financií? Ako vníma exguvernér NBS to, že i napriek trom masívnym konsolidačným kolám sa vláde nedarí skrotiť rozpočtový schodok? Čo podľa neho ohrozuje našu ekonomiku a hrozí Slovensku skutočne bankrot? Ak chceme mať slušnú životnú úroveň, tak jedinou možnosťou pre nás je byť členmi EÚ a mať euro, odkazuje Ivan Šramko.Ako ovplyvní nepredvídateľná a aj agresívna politika Donalda Trumpa svetovú a aj európsku ekonomiku? Obstojí Európa pod tlakom z východu i západu a nemala by byť EÚ voči USA oveľa viac asertívna? Prospelo by Únií viac federácie no a skutočne je dnes EÚ v stave ekonomického úpadku - či je to skôr propaganda neprajníkov Únie? Verejné financie sa stali obeťou krátkodobých politických záujmov, ale je to odrazom - ako i zodpovednosťou, kultúry celej našej spoločnosti, pripomína exguvernér Centrálnej banky.Sledujete Ráno Nahlas, dnes s bývalým guvernérom NBS Ivanom Šramkom. Pekný deň a pokoj v duši praje Braňo Dobšinský.

Vládna konsolidácia škrtí náš ekonomický rast. Problémom sú neadresné vládne výdavky, napr. plošné 13. dôchodky či sociálne benefity i pre tých, ktorí ich vôbec nepotrebujú, tvrdí exguvernér NBS Šramko. Prečo by bol odchod z EÚ pre Slovensko katastrofou a hrozí nám reálny bankrot štátu?Prvý január 2009, deň, v ktorom Slovensko prijalo novú menu a pripojilo sa tak k elitnému euroklubu. Zavedenie eura sprevádzali polemiky ohľadom konverzného kurzu, ale dôvodmi pochybností boli aj možné menové špekulácie, ktoré otvorila návšteva vtedajšieho ministra financií na jachte spolumajiteľa jednej z finančných skupín, za ktorú si vyslúžil od premiéra “žltú kartu.” Jedným z otcov Eura na Slovensku bol aj vtedajší guvernér Národnej banky Slovenska Ivan Šramko. Ako dnes jeden z otcov slovenského eura hodnotí stav slovenskej ekonomiky a aké odporúčanie by dal našej vláde pri zatiaľ neúspešnej konsolidácií verejných financií? Ako vníma exguvernér NBS to, že i napriek trom masívnym konsolidačným kolám sa vláde nedarí skrotiť rozpočtový schodok? Čo podľa neho ohrozuje našu ekonomiku a hrozí Slovensku skutočne bankrot? Ak chceme mať slušnú životnú úroveň, tak jedinou možnosťou pre nás je byť členmi EÚ a mať euro, odkazuje Ivan Šramko.Ako ovplyvní nepredvídateľná a aj agresívna politika Donalda Trumpa svetovú a aj európsku ekonomiku? Obstojí Európa pod tlakom z východu i západu a nemala by byť EÚ voči USA oveľa viac asertívna? Prospelo by Únií viac federácie no a skutočne je dnes EÚ v stave ekonomického úpadku - či je to skôr propaganda neprajníkov Únie? Verejné financie sa stali obeťou krátkodobých politických záujmov, ale je to odrazom - ako i zodpovednosťou, kultúry celej našej spoločnosti, pripomína exguvernér Centrálnej banky.Sledujete Ráno Nahlas, dnes s bývalým guvernérom NBS Ivanom Šramkom. Pekný deň a pokoj v duši praje Braňo Dobšinský.

Tout le monde aspire à être béni. Nous avons tous besoin d'être encouragés, édifiés, complimentés et appréciés. Et vous avez la capacité de bénir les autres. Remerciez Dieu non seulement de vous avoir béni, mais aussi d'avoir fait de vous une bénédiction. Il arrive à chacun de nous d'être las et découragé, et nous avons besoin des autres pour nous montrer que nous avons de la valeur et que nous sommes appréciés. Je suis convaincue que Dieu nous bénit pour que nous soyons en bénédiction – non pas seulement à certains endroits, mais partout où nous allons. Recherchez les personnes qui sont dans le besoin et bénissez-les. Partagez ce que vous avez avec ceux qui ont moins que vous. Et souvenez-vous que tout le monde a besoin d'une bénédiction – même ceux à qui la vie ne semble rien refuser. Lorsque vous consacrez votre vie à soulager les besoins des autres et à encourager ceux qui vous entourent, vous êtes rempli d'une «joie indicible et glorieuse» (1 Pierre 1:8, NBS). Père, je suis infiniment reconnaissant pour tes bénédictions dans ma vie. Merci également parce que je peux être en bénédiction à mon prochain. Aide-moi à aller chaque jour vers lui et à rechercher son bien. — Êtes-vous prêt à aller plus loin ?

This week on the SBK Betting Podcast, Tom Collins, Ross Millar and Sam Twiston-Davies preview a big Cheltenham Trials Day. Sam breaks down his rides at Cheltenham this Saturday, offering insight from the saddle and his take on what to watch.The panel then dive into the weekend's key races, with the Cross Country Handicap Chase, Cleeve Hurdle and the much anticipated clash between Sir Gino and The New Lion in the International Hurdle. What clues will we get for the Cheltenham Festival?As always, the show wraps up with the team's NAPs & NBs.Got a fancy of your own? Drop your predictions in the comments Hosted on Acast. See acast.com/privacy for more information.

Tramps mīkstina retoriku pret NATO sabiedrotajiem, taču savstarpējā neuzticība saglabājas. Eksperte: Transatlantiskie strīdi kaitē Ukrainai; Krievijai tas ir izdevīgi un to var izmantot. Eiropas līderi Briselē pulcējas uz ārkārtas sanāksmi. Rīgā šodien notiek NBS industriju diena – ikgadējs pasākums, kas veltīts jaunajām tehnoloģijām aizsardzības nozarē. Šonedēļ svētki autosporta cienītājiem – pašu mājās ar Alūksnes ralliju sākas vietējā rallija čempionāta sezona, bet šodien Montekarlo apkaimē ar pirmajiem ātrumposmiem startē pasaules rallija čempionāts. Pēc 20 gadu pārtraukuma Latvijā izdota jauna Sarkanā grāmata.

Slovensko prežíva zlé ekonomické časy, vláde sa nedarí vytiahnuť z firiem viac peňazí na daniach a rast HDP v tomto roku môže podľa NBS klesnúť na 0,6%, hoci ministerstvo financií verí, že to bude aspoň 1,3%. Juraj Karpiš, finančný analytik INESS a autor kníh o investovaní, analyzuje nepredvídateľný ekonomický vývoj doma aj v USA. Donald Trump stupňuje agresivitu a colnú vojnu, ale prudký prepad finančných trhov by ho vedel zastaviť v jeho deštruktívnej politike. „Má to svoje rácio, veď už sme to raz zažili,“ hovorí Karpiš. „Keď Trump ohlásil v apríli obrovské clá najmä na Činu, trhy sa prepadli o 20%. Americký minister financií vtedy Trumpovi vysvetlil, že to spolu súvisí a tak rýchlo oznámil 90-dňovú pauzu. Vtedy sa trhy spamätali, lebo pochopili, že Trump je slabý a ustúpil.“ Na trhoch sa už skutočne začal fenomén „debasement trade“, keď sa investori odkláňajú od dolára a preferujú aktíva odolné voči devalvácii. „Ľudia sa začali báť Ameriky a kapitál sa sťahuje z dolárových dlhopisov a aktív, tie strácajú na sile a hore letí zlato,“ upozorňuje analytik. Zlato skutočne za minulý rok zvýšilo svoju hodnotu o 70%, čo najprudší rast za posledných 50 rokov. Podľa Karpiša je to varovný signál, že je zle. „Za posledné dva roky vidíme najväčší nárast hodnoty zlata v modernej histórii. Je to indikátor, že prežívame zlé ekonomické a politické scenáre.“ Aktuálne dianie skresľuje pohľad investorov. „Ľudia sa často pozerajú na svoje výnosy a vravia si, že americké akcie im zarobili 20%. Ale v skutočnosti sledujú len oslabenie amerického dolára. Ak si to premenia na eurá, tak sú na nule a v českých korunách sú v mínuse,“ vysvetľuje analytik. Dodáva, že stále sme len na začiatku tohto procesu a naplno sa môže prejaviť po máji 2026, keď sa skončí mandát súčasnému šéfovi FEDu a ukáže sa, či Donald Trump dokáže presadiť svoju politiku nízkych úrokových sadzieb. Juraj Karpiš zároveň približuje, ako funguje kryptomena stablecoin, ktorá má potenciál vytvoriť celý nový sektor a vziať bankám veľkú časť trhu. „Ak ho nezakážu, môže vyvolať revolúciu v platobnom styku.“ Ako sa v tomto svete má zachovať slovenský investor? Pozrite si celý diel relácie Index s Jurajom Karpišom. Moderuje Eva Mihočková. V rozhovore sa dozviete: Vyhýbajú sa firmy plateniu daní, alebo už skrátka nevládzu? Môžu Donalda Trumpa zastaviť finančné trhy? Prečo sa investori začali báť amerických dlhopisov Prečo zlato narástlo o 70% Ako Amerika ničí sama seba a postavenie dolára Ako sa dajú využiť stablecoiny See omnystudio.com/listener for privacy information.

Hostia: Erik Tomáš (minister práce, sociálnych vecí a rodiny SR), Monika Uhlerová (prezidentka Konfederácie odborových zväzov) a Rastislav Machunka (prezident Asociácie zamestnávateľských zväzov a združení). | Index trhu práce dosahuje podľa ManpowerGroup najhoršiu hodnotu za posledných päť rokov – takmer tretina zamestnávateľov očakáva v najbližšom období prepúšťanie. Miera dosahuje nezamestnanosti v decembri stúpla na 6,08 %. Pribúdajú nezamestnaní najmä zo stavebníctva, obchodu, služieb a dopravy. Na druhej strane, stagnácia odtokov z evidencie naznačuje, že schopnosť trhu práce absorbovať nezamestnaných sa oslabuje, konštatuje NBS. Čo sú hlavné dôvody avizovaného prepúšťania? Sú zamestnávatelia pod zvýšeným tlakom? Sú súčasné nástroje štátu (aktívna politika trhu práce, rekvalifikácie) dostatočne flexibilné a rýchle na to, aby pomohli prepusteným ľuďom? Je súčasné prepúšťanie len dočasným reakčným krokom na ekonomické spomalenie, alebo sme svedkami trvalejších štrukturálnych zmien (napr. automatizácia, AI)? Ktoré regióny Slovenska sú najviac ohrozené? Hrozí prehlbovanie regionálnych rozdielov, keďže stavebníctvo a priemysel sú kľúčové práve v regiónoch s vyššou nezamestnanosťou? Aké sú predikcie, ako sa bude vyvíjať trh práce v tomto roku? Nakoľko prudký bude nárast nezamestnanosti? Dokáže pracovný trh uvoľnených zamestnancov absorbovať – spĺňajú nároky a požiadavky? V akej pozícii sa ocitajú prepustení zamestnanci – napríklad aj vzhľadom na skrátenie obdobia vyplácania dávok v nezamestnanosti? | Trh práce čelí prepúšťaniu. | Moderuje: Marta Jančkárová; | Diskusiu Z prvej ruky pripravuje Slovenský rozhlas, Rádio Slovensko, SRo1. Vysielame každý pracovný deň o 12:30 v Rádiu Slovensko.

China's economy demonstrated strong resilience in 2025, with growth holding firm despite mounting external pressures and internal structural adjustments, while new growth drivers are taking shape to support sustainable expansion going forward, said officials and experts.政府工作人员和专家指出，2025年中国经济展现出强劲韧性，在外部压力不断加剧和内部结构调整的双重背景下，经济增长依然保持稳健，同时新的增长动力正在形成，为未来可持续扩张提供支撑。Official data released on Monday showed that China's gross domestic product grew 5 percent last year, meeting the country's annual target of around 5 percent. The hard-won performance, achieved amid heightened tariff pressures, has laid a solid foundation for a steady start to economic growth in 2026, reinforcing confidence that the world's second-largest economy remains on a stable trajectory.官方周一公布的数据显示，中国去年国内生产总值增长5%，实现了约5%的年度增长目标。在关税压力加剧的背景下取得的这一来之不易的成绩，为2026年经济增长平稳开局奠定了坚实基础，增强了市场信心，表明这个全球第二大经济体仍保持着稳定发展态势。As China enters the opening year of its 15th Five-Year Plan (2026-30) period, economists said policymakers are set to press ahead with front-loaded fiscal support to boost domestic demand, alongside a moderately accommodative monetary stance aimed at lifting prices and easing financing costs.随着中国迎来第十五个五年规划（2026-2030年）的开局之年，经济学家指出，政策制定者将推进前置性财政支持以提振内需，同时采取适度宽松的货币政策立场，旨在提振物价并降低融资成本。The country's annual GDP came in at 140.19 trillion yuan ($20.13 trillion) in 2025, according to the National Bureau of Statistics. In the fourth quarter of 2025, the Chinese economy grew 4.5 percent year-on-year, following 4.8 percent growth in the third quarter.国家统计局数据显示，2025年中国国内生产总值（GDP）达140.19万亿元（合20.13万亿美元）。2025年第四季度，中国经济同比增长4.5%，此前第三季度增速为4.8%。Kang Yi, head of the NBS, said that the latest indicators fully demonstrate the Chinese economy's steady progress, resilience under pressure, and vitality in moving toward higher-quality and innovation-driven development.国家统计局局长康义表示，最新指标充分展现了中国经济稳步前进的态势、在压力下的韧性，以及在迈向更高质量、创新驱动发展道路上的活力。"China's average annual contribution to global economic growth stood at around 30 percent throughout the 14th Five-Year Plan (2021-25) period. With a complete industrial system, China has played a stabilizing role in global supply chains and injected much-needed stability into a world economy undergoing turbulence and transformation," he said.中国在“十四五”规划（2021-2025年）期间，对全球经济增长的年均贡献率保持在30%左右。凭借完整的产业链体系，中国在全球供应链中发挥着稳定器作用，为动荡转型中的世界经济注入了急需的稳定力量。Guan Tao, global chief economist at BOCI China, said that China's economy has delivered "hard-won" results in 2025, featuring breakthroughs in technological advances and emerging consumption phenomena, setting the stage for a 2026 GDP growth target possibly at 4.5 percent to 5 percent.中银证券全球首席经济学家管涛表示，2025年中国经济取得“来之不易”的成果，技术进步实现突破性进展，消费呈现新形态，为2026年GDP增速目标设定4.5%至5%的区间奠定基础。"In 2025, when people talked about China, things like DeepSeek, Ne Zha 2, Unitree humanoid robots, the overseas expansion of innovative pharmaceuticals, and Jiangsu Football City League, or Suchao, all showed that China's economy has been full of highlights, whether in consumption recovery or technological innovation," Guan said.管涛表示：“在2025年，当人们谈论中国时，话题转向了诸如DeepSeek、《哪吒2》、宇树人形机器人、创新药出海、江苏城市足球联赛‘苏超'等新事物；焦点无论是消费复苏还是科技创新，都展现出中国经济的亮点纷呈；都无不印证着中国经济的蓬勃生机。”Citing the latest indicators, Sheana Yue, a senior economist at British think tank Oxford Economics, said that the fourth quarter's continued momentum appeared to be driven by stronger industrial activity and exports in December, which offset still weak domestic demand.英国智库牛津经济研究院高级经济学家岳喜娜援引最新指标指出，第四季度经济持续增长的动能似乎源于12月工业活动和出口的强劲表现，这抵消了国内需求依然疲软的影响。NBS data showed that China's value-added industrial output rose 5.2 percent in December, following 4.8 percent growth in November.国家统计局数据显示，中国12月工业增加值同比增长5.2%，高于11月的4.8%增速。"Our estimates suggested high-tech manufacturing, including transport equipment, electrical machinery and electronics manufacturing, continued to outperform at the end of 2025," Yue said.岳喜娜：“我们的估算显示，包括运输设备、电机和电子制造在内的高科技制造业，在2025年底仍保持着强劲增长态势。”According to the NBS, retail sales, a key indicator of consumer spending, increased 0.9 percent in December, while China's fixed-asset investment decreased 3.8 percent in 2025.据国家统计局数据显示，作为消费支出重要指标的零售额在12月增长0.9%，而2025年中国固定资产投资同比下降3.8%。Wang Qing, chief macroeconomic analyst at Golden Credit Rating International, said that looking ahead to 2026, the impact of high tariffs imposed by the United States on global trade and China's exports is expected to become more pronounced, weakening the contribution of external demand to economic growth and requiring domestic demand to step in more decisively.东方金诚首席宏观分析师王青表示，展望2026年，美国高关税对全球贸易和中国出口的影响预计将更加显著，这将削弱外需对经济增长的贡献，需要内需更果断地接棒。"We expect that, with more proactive and effective macroeconomic policies continuing to gain strength, consumption will accelerate further in 2026, and investment will stabilize after bottoming out," he said.王青表示：“随着更积极有效的宏观经济政策持续发力，预计2026年消费将进一步加速增长，投资将在触底后趋于稳定。”With 2026 marking the opening year of China's 15th Five-Year Plan, Xu Hongcai, deputy director of the economic policy committee of the China Association of Policy Science, said that ensuring a smooth economic start will be critical, and called for stable, consistent and moderately forceful macro policies.2026年标志着中国第十五个五年规划的开局之年。中国政策科学研究会常务理事、经济政策委员会副主任徐洪才指出，确保经济平稳开局至关重要，呼吁实施稳定、连贯且力度适中的宏观政策。Fiscal policy should remain proactive, he said, suggesting that the fiscal deficit ratio remain at around 4 percent, supported by the continued issuance of long-term treasuries to boost consumption, improve public well-being and mitigate local government debt risks. He added that monetary policy should stay moderately accommodative, with room for further cuts to interest rates and the reserve requirement ratio.徐洪才表示，财政政策应保持积极，建议财政赤字率维持在4%左右，同时继续发行长期国债以提振消费、改善民生并缓解地方政府债务风险。他还指出，货币政策应保持适度宽松，存在进一步下调利率和存款准备金率的空间。Going forward, Xu said that China's economic growth in 2026 is expected to remain within a reasonable range, with improving quality, a more optimized structure and steady progress toward high-quality development.徐洪才表示，展望未来，2026年中国经济增长预计将保持在合理区间，质量不断提升，结构持续优化，朝着高质量发展稳步迈进。Choi Yong-ho, chief executive officer and chief happiness officer of South Korean entertainment technology company Galaxy Corp, said China's market holds virtually unlimited development potential. "It is creative, innovative and dynamic, and it is already at the global forefront in multiple industries."韩国娱乐科技独角兽Galaxy Corp首席执行官兼首席幸福官崔龙湖表示，中国市场蕴藏着几乎无限的发展潜力。“这个市场充满创造力、创新精神和活力，已在多个行业处于全球领先地位。”"China's strong capabilities in robotics and artificial intelligence are leading industrial development, and its younger generation represents a highly capable and promising talent base. With these advantages, I believe the Chinese market will continue to grow, with a very optimistic outlook," he said.崔龙湖表示：“中国在机器人和人工智能领域的强大实力正引领着工业发展，其年轻一代代表着一支能力出众、充满希望的人才队伍。凭借这些优势，我相信中国市场将继续增长，前景非常乐观。”humanoid robot/ˈhjuː.mə.nɔɪd/n.人形机器人trajectory/trəˈdʒek.tɚ.i/n.轨道；态势

Hostia: Marián Labaj (analytik NBS) a Radovan Geist (šéfredaktor Euractiv). | Tento rok /2026/ je z hľadiska čerpania eurofondov rozhodujúci. Je to totiž posledný rok, keď sa dajú v aktuálnom programovom období /2021 – 2027/ reálne rozbehnúť a zazmluvniť projekty – inak Slovensku hrozí, že časť peňazí prepadne. Čo sa stane, ak peniaze nestihneme využiť? Kto dnes na eurofondy dosiahne a kto naopak vypadáva zo systému pre jeho zložitosť? Počúvajte Kontakty s Evou Sládkovou. | Eurofondy v roku 2026. | Moderuje: Eva Sládková; | Kontakty pripravuje Slovenský rozhlas, Rádio Slovensko, SRo1. V premiére v pondelok až štvrtok po 20. hodine v Rádiu Slovensko.

Besprochene Urteile1. Strafrecht: Gefälschtes Innenministerin-Foto – erst Verurteilung, dann FreispruchAG Bamberg, Urteil vom 08.04.2025 – 27 Cs 1108 Js 11315/24 (2) LG Bamberg, Urteil vom 14.01.2026 – 11 NBs 1108 Js 11315/24Manipuliertes Foto von Nancy Faeser mit Text "Ich hasse die Meinungsfreiheit" – AG verurteilte zu sieben Monaten Bewährung wegen Verleumdung (§ 188 StGB), LG sprach frei. 2. Waffenrecht: Einkürzen einer Handfackel ist unerlaubter Umgang mit ExplosivstoffenOLG Hamm, Beschluss vom 13.01.2026 – (Az. nicht veröffentlicht)Wer Griffstück einer Handfackel von 120 mm auf 4 mm kürzt, geht unerlaubt mit explosionsgefährlichen Stoffen um. 3. Gaststättenrecht: Shishabar darf keine Shishas mehr servierenVG Mainz, Beschluss vom 29.12.2025 – 1 L 693/25.MZUntersagung der Shisha-Zubereitung trotz bestehender Gaststättenerlaubnis zulässig bei jahrelangen Sicherheitsverstößen. 4. Polizeirecht: Schmerzgriff-Urteil rechtskräftig – aus formalen GründenOVG Berlin-Brandenburg, Beschluss vom 08.01.2026 – OVG 6 N 63/25Berufungszulassung der Berliner Polizei abgelehnt – VG-Urteil zu unverhältnismäßigem Schmerzgriff gegen "Klimakleber" rechtskräftig. 5. Zivilprozessrecht: Truhe im Hausflur als wirksame ZustelladresseLG Lübeck, Urteil vom 18.12.2025 – 15 O 191/24Jahrzehntelange Praxis der Postablage auf Truhe im Hausflur ist wirksame Ersatzzustellung nach § 180 Satz 1 ZPO – auch bei Mitnutzung durch Dritte. Postbote legte seit Jahrzehnten im Einvernehmen Post auf Truhe im nicht verschließbaren Vorraum. Support the show

This week on the pod, Tom Collins and Ross Millar are joined by Sam Twiston-Davies for a brilliant weekend preview. Sam discusses his potential link up with Paul Nicholls and how Constitution Hill could go on the flat before covering his weekend rides.The panel then turn their attention to a cracking weekend of racing, analysing the Rossington Novices' Hurdle and Peter Marsh Handicap Chase from Haydock before the Clarence House Chase at Ascot which could have a big impact on the Cheltenham Festival.As always, the show finishes with the team's NAPs & NBs.Fancy something yourself this weekend? Drop your selections in the comments Hosted on Acast. See acast.com/privacy for more information.

1. Centrálne banky pritvrdzujú pri investičných hypotékach. Signály vysiela už aj NBS 2. Po Američanoch a Európskej komisii utajovanú dohodu s USA o novej atómke definitívne potvrdila aj vláda 3. Akcie zbrojárskych firiem vlani predbehli aj sektor AI. Európa zbrojí a potrebuje na to kapitál 4. Krátko o pripravovanej zábezpeke pri registrácii na DPH, zakladaní a zánikoch firiem a o nových zelených úveroch dotovaných z eurofondov

China's consumer inflation accelerated to its fastest pace in nearly three years in December, official data showed on Friday, signaling a stabilizing economy as recent stimulus measures continued to bolster domestic demand.Going forward, analysts said consumer inflation is expected to remain mild through 2026, leaving ample room for policymakers to step up macroeconomic adjustment to counter mounting uncertainties. Policy options include targeted measures to boost domestic demand and support innovation, as well as further cuts to the reserve requirement ratio and interest rates.The country's consumer price index, the main gauge of inflation, rose by 0.8 percent year-on-year in December, following a 0.7 percent rise in November, marking the highest level since February 2023, the National Bureau of Statistics said on Friday."China's latest consumer inflation data points to a continued strengthening in domestic demand, mainly driven by the impact of consumption-boosting policies and the release of demand ahead of the New Year holiday," said Tang Guang hua, an analyst at Shen yin & Wan guo Futures Co. "Meanwhile, the core CPI remained above 1 percent for four consecutive months in December, highlighting a steady improvement in consumption fundamentals."The improving inflation data has reflected the growing momentum of the Chinese economy, with the World Bank, the International Monetary Fund and the Asian Development Bank having raised their growth forecasts for China's economy.The IMF forecasts a 5 percent GDP expansion in 2025 and 4.5 percent for 2026, while Goldman Sachs said this week that it expects China's GDP to grow 4.8 percent in real terms in 2026, supported by a policy-backed investment rebound, the potential of service consumption, resilient export growth and a milder drag of the property sector.With economic momentum showing signs of improving, Chinese stocks moved higher on Friday, with the Shanghai Composite Index posting a solid gain of 0.92 percent to close at 4,120.43 points, topping the psychologically important 4,100 points to reach a decade high. Since the beginning of the year, the index has risen by 3.82 percent, indicating a continuous improvement in investor confidence.NBS data showed the core CPI, which excludes volatile food and energy prices and is deemed a better gauge of supply-demand conditions, rose 1.2 percent year-on-year in December, unchanged from November.Meanwhile, China's producer price index — which measures factory-gate prices — fell by 1.9 percent year-on-year in December, narrowing from a 2.2 percent drop in November, the NBS said.Tang from Shenyin & Wanguo Futures Co said the narrowing decline in factory-gate prices showed strengthening recovery momentum, signaling both improving industrial fundamentals and deeper structural optimization.He expects consumer prices to rise steadily on the back of continued consumption recovery and policy support, while PPI recovery momentum is set to strengthen further given the progress in building a unified national market, industrial restructuring and rising demand from emerging industries as key drivers, particularly for high-end manufacturing.As the NBS is set to release the economic indicators for December and the fourth quarter later this month, Li Chao, chief economist at Zheshang Securities, said China's economic growth is expected to have remained resilient toward the end of 2025, fueled by relatively strong production and a gradual recovery in demand.He said that economic activity likely picked up in December, with both domestic and external demand gradually improving and companies pushing to meet year-end targets. "That will help support China to achieve its full-year growth target of around 5 percent in 2025, while laying the groundwork for a strong start in 2026."During the recently held 2026 work conference of the People's Bank of China, the country's central bank said it will continue to implement an appropriately accommodative monetary policy in 2026, underscoring its commitment to supporting high-quality economic development and promoting a reasonable rebound in prices.Li from Zheshang Securities said his team expects a 50 basis-point cut in the RRR and a 10 basis-point reduction in policy interest rates over the year.Li added that structural policy tools are expected to continue to play a key role, alongside stronger credit guidance to channel funding toward priority areas.Expanding domestic demand, advancing technological innovation and supporting micro, small and medium-sized enterprises are likely to remain the main focus of policy support in 2026, he said.

This week's podcast sees Tom Collins and Ross Millar joined again by Sam Twiston-Davies. TC chats with Sam about his recent win on Matata and his rides this Saturday, before the panel break down the weekend's feature races, including the Silviniaco Conti Chase, Half A Mill Handicap Chase, and the Lanzarote Handicap Hurdle, finishing with their NAPs and NBs.Got a fancy of your own this weekend? Drop your selections in the comments. Hosted on Acast. See acast.com/privacy for more information.

In this hour of VSiN By The Books, hosts Jensen Lewis and Dave Ross recap yesterday's top sports headlines. Plus, the guys break down their week 18 survivor leans. Also, don't miss today's edition of the “Daily Gridiron", as Jensen and Dave find different ways to attack the football market. Get instant access to expert picks, public betting splits data, and pro betting tools when you join VSiN pro. Grab your first month for only $9.99 or take over 15% off an annual subscription when you use promo code: POD25. Click Here to get started. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

After a star-studded week of Christmas racing, Tom Collins and Ross Millar are joined once again by Sam Twiston-Davies to reflect on it all including THAT King George and preview Cheltenham's New Year's Day meeting.The panel turns its attention to Prestbury Park, breaking down the key races including the Chasing Excellence Novices' Chase, the Betfair Exchange Handicap Chase, and the Relkeel HurdleAs ever, the pod is rounded off with their NAPs and NBs for New Year's Day.Got a fancy to kick off the year? Drop your selections in the comments. Hosted on Acast. See acast.com/privacy for more information.

With a packed festive schedule just around the corner, Tom Collins and Ross Millar return to preview all the weekend's racing from Ascot and Haydock. They dive into four feature races before rounding off with their NAPs & NBs.00:00 - Intro03:12 - Tommy Whittle Handicap Chase07:37 - Long Walk Hurdle12:35 - Silver Cup18:20 - Festive Handicap Hurdle22:30 - NAP & NBsDownload SBK: https://betsbk.comFollow us on X - https://x.com/sbkFollow Tom Collins: X - https://x.com/TomptinFollow Ross Millar X- https://x.com/rosscojmillInstagram - https://www.instagram.com/rossmillarracing?igsh=azhwdzJodmlkaHFi Hosted on Acast. See acast.com/privacy for more information.

Almost every business owner knows they need to spend time working ON and not just IN their business. But what does it mean to take that concept to a whole new level by traveling and spending time outdoors with colleagues and strategic partners? Whether you choose to take time out of your business to work on your business and do it across town or across the country, this conversation with Drs. Julie Helmus, OD and Paul Mormon, OD talk about what it takes and means to truly invest in yourself by finding your tribe and community. This is also a perfect time to remind you, the listener, that in addition to sharing what Paul has created with GRT, the concepts and benefits we're discussing in today's episode are what we are striving to accomplish with OD Masterminds (link in the show notes). The important NBS for you: find your tribe and structure that fits you best—and helps you make progress.   Resources: Book a Triage call with Adam Download the Practice Owner's Financial Toolkit 20/20 Money Ultimate Financial Success Masterclass OD Mastermind Interest Form GRT Summit PERC IDOC   ————————————————————————————— Please rate and subscribe to 20/20 Money on these platforms Apple Podcasts Spotify ————————————————————————————— For past episodes of 20/20 Money with full companion show notes, please check out our episode archive here!

The Cheltenham December Meeting takes centre stage this week and Tom Collins and Ross Millar are back with their full rundown.The spotlight is firmly on Prestbury Park where the December Gold Cup and Albert Bartlett Novices' Hurdle before crossing over to Doncaster for the Listed Mares' Hurdle.As always, the lads finish the podcast with their NAPs and NBs from across Saturday's cards Hosted on Acast. See acast.com/privacy for more information.

After a huge weekend featuring the Fighting Fifth and the Coral Gold Cup, Tom Collins and Ross Millar are back to look ahead to another cracking set of races. This week the spotlight starts at Sandown where Lulamba and Jonbon go in search of victories in the Henry VIII and Tingle Creek respectively. We then travel over to Aintree for the Becher Chase. As always, they wrap up with their NAPs and NBs.Who will you be following this weekend? Hosted on Acast. See acast.com/privacy for more information.

NBS Štāba orķestra klarnešu kvartets ''Quattro Differente'' turpina 25. jubilejas koncertu sēriju, 3. decembrī plkst.18.00 uzstājoties Liepājas koncertzāles "Lielais dzintars" kamerzālē, bet 5. decembrī plkst. 19.00 - Latvijas Nacionālās bibliotēkas Ziedoņa zālē. Par visu plašāk trešdienas "Neatliekamajā sarunā" vēsta kvarteta dalībnieki Marina Vidmonte un Guntars Gedroics.

After a big weekend at Haydock and Punchestown, Tom Collins and Ross Millar return with another action-packed episode previewing the weekend's two major clashes: the Fighting Fifth Hurdle and the Coral Gold Cup. The lads dive into the headline showdown between Constitution Hill and The New Lion and break down the key contenders in Newbury's showpiece. NAPs & NBs then round off this week's podcast. Let us know who will you be following this Saturday? Hosted on Acast. See acast.com/privacy for more information.

Šajās dienās mēs svinam savu brīvību. Bet Ukrainā cilvēki joprojām ziedo dzīvības par savu. Gan karavīri frontē, gan brīvprātīgie, gan mierīgie iedzīvotāji, kuru dzīvi jebkurā brīdī var pārtraukt ienaidnieka raķete vai drons. Kopā ar ukraiņiem cīnās arī karotāji no Latvijas, un mūsu sabiedrība kopumā turpina atbalstīt ukraiņu cīņu, kaut arī rit jau ceturtais kara gads. Mums studijā pievienojas divi no brīvprātīgā atbalsta organizatoriem – Elmārs Pļaviņš, NBS vecākais eksperts starptautiski militāri reliģiskos jautājumos un fonda “Uzņēmēji mieram” vadītāja Laura Skrodele.

Cheltenham's November meeting takes centre stage on this week's podcast with Tom Collins and Ross Millar lining up their best bets for the weekend. In this jam-packed show, the panel look for Festival clues with Albert Bartlett Hurdle, Triumph Hurdle and Arkle Trials. The focus then switches to the weekend's main event, the Paddy Power Gold Cup. NAPs & NBs round off this week's show. Let us know which horse you are looking forward to seeing this weekend below... Hosted on Acast. See acast.com/privacy for more information.

In this edition of First Site, Construction News deputy editor Ben Vogel explores the fast-emerging world of digital product passports and their implications for transparency, accountability and sustainability across the construction supply chain. Joining him to unpack how the technology could reshape regulation, procurement and data management are Peter Caplehorn, chief executive of the Construction Products Association; Dr Stephen Hamil, innovation director at NBS; and Matt Brinklow, sustainability lead at Mace. 

Hostia: Marián Labaj (analytik NBS) a Radovan Geist (šéfredaktor Euractiv). | Myšlienka eurofodov vznikla v Európskej únii v polovici minulého storočia. Bohatšie štáty cez ne prispievajú na rozvoj tých chudobnejších. Pre Slovensko sú eurofondy mimoriadne dôležité, ročne k nám takto pritečú miliardy eur. Mohlo by ale viac. Prečo slabo čerpáme eurofondy? A ako to zmeniť? Počúvajte Kontakty s Evou Sládkovou. | Čerpanie eurofondov. | Moderuje: Eva Sládková; | Kontakty pripravuje Slovenský rozhlas, Rádio Slovensko, SRo1. V premiére v pondelok až štvrtok po 20. hodine v Rádiu Slovensko.

Show Notes: Shifting political priorities and economic pressures over the past couple of years have seen several countries scale back climate commitments contributing to the growing gap between climate pledges and real-world emissions (still rising).What does this mean for a ‘Just Transition' and Net Zero? While there is no silver bullet, IUCN and UNEP emphasise Nature based Solutions (NbS) can be pivotal for climate mitigation and adaptation, when pursued alongside rapid decarbonisation globally.To discuss NbS, and climate change I recently caught up with Swapan Mehra a global leader in climate action and ecosystem conservation. In this deeply insightful conversation Swapan spoke about how NbS is a holistic approach to addressing the climate crisis, through a spectrum of actions designed to protect and restore ecosystems while simultaneously delivering co-benefits for biodiversity, communities and individuals. We also spoke about…

China's industrial profits grew at its fastest pace in nearly two years in September, official data showed on Monday, as policy measures to rein in rat-race competition helped ease pressure on manufacturers despite lingering domestic and external headwinds.官方数据于周一显示，尽管国内外不利因素仍存，但随着遏制无序竞争的政策措施帮助缓解了制造商的压力，9月中国工业利润增速达到近两年来的最高水平。Analysts attributed the rebound in corporate profitability to firmer prices and resilient industrial output, supported by Beijing's pro-growth policies, pointing to a stabilizing economy buoyed by the strong performance of the new quality productive forces.分析师认为，在国家稳增长政策的支撑下，产品价格趋稳以及工业产出保持韧性，推动了企业盈利能力的回升。他们指出，得益于新质生产力的良好发展态势，中国经济正趋于稳定。Looking ahead, they expect the recovery momentum to extend into the fourth quarter, with policymakers likely to intensify countercyclical adjustments to boost domestic demand, spur market confidence and reinforce internal growth drivers — keeping China on track to meet its full-year growth target.展望未来，分析师预计复苏势头将延续至第四季度。政策制定者可能会加大逆周期调节力度，以扩大内需、提振市场信心并强化内生增长动力，确保中国能够实现全年经济增长目标。China's industrial enterprises with an annual revenue of at least 20 million yuan ($2.8 million) saw their total profits soar 21.6 percent year-on-year in September, following a 20.4 percent jump in August, marking the largest gain since November 2023, data from the National Bureau of Statistics showed on Monday.国家统计局周一发布的数据显示，9月，年营业收入2000万元（约合280万美元）及以上的中国工业企业，其实现利润总额同比激增21.6%；8月该指标同比增幅为20.4%。这意味着9月工业利润增幅创下2023年11月以来的最高纪录。During the first nine months of the year, profits at major industrial companies grew to 5.37 trillion yuan, a year-on-year increase of 3.2 percent, following a 0.9 percent rise in the first eight months.今年前9个月，规模以上工业企业实现利润5.37万亿元，同比增长3.2%；前8个月该指标同比增幅为0.9%。Wen Bin, chief economist at China Minsheng Bank, said: "The strong growth in September's industrial profits was largely driven by a low base from last year, combined with stabilizing production, easing price pressures and improving profit margins."中国民生银行首席经济学家温彬表示：“9月工业利润的强劲增长，很大程度上得益于去年同期的低基数效应，同时也受到生产企稳、价格压力缓解以及利润率改善等因素的综合推动。”NBS data showed China's industrial output surged 6.5 percent year-on-year in September after a 5.2 percent rise in August, marking the first acceleration in three months.国家统计局数据显示，9月中国工业增加值同比增长6.5%，较8月的5.2%有所提升，这是该指标近三个月来首次出现增速加快。Meanwhile, China's producer price index — which measures factory-gate prices — fell 2.3 percent year-on-year in September, easing from a 2.9 percent drop in August.与此同时，9月中国工业品出厂价格指数（PPI，衡量工厂端产品价格水平）同比下降2.3%，降幅较8月的2.9%有所收窄。Wen also noted that "structural bright spots are a key part of the rebound in corporate profitability", underpinned by the robust performance of high-tech manufacturing and equipment manufacturing sectors.温彬还指出，“结构性亮点是企业盈利能力回升的关键因素”，而高新技术制造业和装备制造业的强劲表现为这一亮点提供了支撑。According to the NBS, profits in high-tech manufacturing industries surged 26.8 percent in September, driving overall industrial profit growth to accelerate by 6.1 percentage points.国家统计局数据显示，9月高新技术制造业利润同比激增26.8%，拉动全部工业利润增速加快6.1个百分点。For the first nine months, profits in equipment manufacturing industries soared 9.4 percent, contributing 3.4 percentage points to overall profit growth.今年前9个月，装备制造业利润同比大幅增长9.4%，对全部工业利润增长的贡献率达到3.4个百分点。Citing the faster profit growth among private sector and foreign companies, Wen said that it indicates market expectations are improving, and business confidence is recovering.温彬提到，私营企业和外资企业利润增速加快，这表明市场预期正在改善，企业信心逐步恢复。Looking ahead, he said the fourth quarter will likely see steady growth in industrial profits with the government's effective measures to curb involution competition, easing price pressures and improving corporate profitability.他表示，展望未来，随着政府采取有效措施遏制行业内卷、价格压力进一步缓解以及企业盈利能力持续改善，第四季度工业利润有望保持稳定增长。In the communique of the fourth plenary session of the 20th Central Committee of the Communist Party of China, which was released on Thursday, policymakers called for "resolutely achieving the economic and social targets set for this year", suggesting they will ensure GDP growth will reach the "around 5 percent" growth target.中共二十届四中全会公报于周四发布，其中政策制定者提出“坚决完成今年经济社会发展目标任务”，这一表述意味着政府将确保国内生产总值（GDP）实现“5%左右”的增长目标。Lu Ting, chief China economist at Nomura, said he expects the country to refocus on short-term growth stability. "Beijing just needs around 4.2 percent GDP growth in the fourth quarter to deliver that target. So, from a statistics perspective, it's easily within reach," he said.野村证券首席中国经济学家陆挺表示，预计中国将重新聚焦短期经济稳定增长。他指出：“要实现全年增长目标，中国第四季度GDP增速只需达到4.2%左右即可。因此，从统计角度来看，这一目标触手可及。”The best strategy is to resist the temptation to fuel the stock markets by avoiding too high-profile monetary measures in the near term, remaining vigilant by avoiding contractionary policies, cleaning up the property market problem, and addressing some deep-rooted problems such as the unequal social security system, Lu said.陆挺认为，当前最佳策略是：短期内避免推出过于高调的货币政策，抵制刺激股市的诱惑；保持警惕，不采取紧缩性政策；着力解决房地产市场问题；并应对一些深层次问题，如社会保障体系不均衡等。A report released by the Chinese Academy of Social Sciences' Institute of Finance & Banking on Monday noted that insufficient effective demand remains a prominent challenge.中国社会科学院金融研究所周一发布的一份报告指出，有效需求不足仍是当前面临的突出挑战。Against the backdrop of US-China trade friction and profound structural economic shifts, the report said China should advance macroeconomic governance system innovation that addresses both existing structures and new growth drivers, with a focus on enhancing policy efficacy.报告称，在美国对华贸易摩擦以及国内经济结构性深刻调整的背景下，中国应推进兼顾现有结构与新增动力的宏观经济治理体系改革，并重点提升政策实施效果。"In the short term, macro policies should be proactively strengthened, including more forceful fiscal spending tilted toward consumption stimulation, utilizing the room for interest rate cuts and reserve requirement ratio reductions created by the US Federal Reserve's move, and implementing multi-pronged measures to stabilize the property market and foster its high-quality development," said Wang Qing, assistant researcher at the institute.该研究所助理研究员王青（音译）表示：“短期内，应积极加大宏观政策力度，包括采取更有力的财政支出措施并向刺激消费倾斜、利用美联储政策调整所带来的降息降准空间，以及通过多方面举措稳定房地产市场、推动其高质量发展。”resilient/rɪˈzɪliənt/adj.能快速恢复的，具韧性的countercyclical/ˌkaʊntəˈsaɪklɪkl/adj.反经济周期的

Realita verzus sen, alebo realita a snaha o jej prekrytie? Otázky, ktoré sa natískajú po víkendovom snemovaní vládneho Smeru. Robert Fico ponúkol svojej strane „Desatoro“, ktorého deklarovaným cieľom sú riadne, nie predčasné voľby a víťazstvo Smeru.Ako to vyznieva v čase, keď prieskumy verejnej mienky zachytávajú len ďalší prepad jeho strany; keď kladie nohu do dverí pri návrhu opätovnej voľby Petra Kažimíra do čela NBS, ktorého sa nechce vzdať koaličný Hlas; keď otvára tému predlžovania mandátu obecných zastupiteľstiev; keď čelí zdražovaniu, konsolidačnému tlaku a rastúcemu zadlžovaniu krajiny, čo kritizuje aj rozpočtová rada.Pozrieme sa na to politológom Radoslavom Štefančíkom.Budete počuť aj Vladimíra Amricha, s ktorým sa pozrieme na vládny návrh štátneho rozpočtu, ako i na jeho hodnotenie zo strany Rady pre rozpočtovú zodpovednosť.Podcast pripravil Jaroslav Barborák.

Realita verzus sen, alebo realita a snaha o jej prekrytie? Otázky, ktoré sa natískajú po víkendovom snemovaní vládneho Smeru. Robert Fico ponúkol svojej strane „Desatoro“, ktorého deklarovaným cieľom sú riadne, nie predčasné voľby a víťazstvo Smeru.Ako to vyznieva v čase, keď prieskumy verejnej mienky zachytávajú len ďalší prepad jeho strany; keď kladie nohu do dverí pri návrhu opätovnej voľby Petra Kažimíra do čela NBS, ktorého sa nechce vzdať koaličný Hlas; keď otvára tému predlžovania mandátu obecných zastupiteľstiev; keď čelí zdražovaniu, konsolidačnému tlaku a rastúcemu zadlžovaniu krajiny, čo kritizuje aj rozpočtová rada.Pozrieme sa na to politológom Radoslavom Štefančíkom.Budete počuť aj Vladimíra Amricha, s ktorým sa pozrieme na vládny návrh štátneho rozpočtu, ako i na jeho hodnotenie zo strany Rady pre rozpočtovú zodpovednosť.Podcast pripravil Jaroslav Barborák.

Tretia konsolidácia Ficovej vlády ohrozila sociálny zmier. Proti konsolidácii aj rozpočtu protestujú odborári aj opozícia. Vláda zmrazila trináste dôchodky a Smer navyše hovorí o ich adresnosti. Stámilióny na energopomoc nemôže vláda zaplatiť z eurofondov. Konsolidácia dostáva trhliny a neverí je ani Národná banka.Čo s tým urobí vládny Hlas a čo chce urobiť s tým, že mu už rok padajú voličské preferencie? Prečo je podľa premiéra Peter Kažimír zradca a prečo NBS neverí vládnej konsolidácii? A čo hovorí Hlas na nápad premiéra posunúť voľby do obcí, miest a krajov o ďalší rok? Aký je na to vlastne dôvod?Braňo Závodský sa rozprával s ministrom práce sociálnych vecí a rodiny a podpredsedom strany Hlas – SD Erikom Tomášom.

Yesterday, Building and Construction Minister Chris Penk announced changes to the earthquake-prone building regulations that will remove nearly 3000 buildings from the classification register.   Previously, buildings would have to meet a 34%NBS (new building standard) threshold to predict likelihoods of withstanding seismic action. The new system instead prioritises identifying structures that pose a higher risk to human life. Alterations seek to measure risk in a manner that balances safety with more affordable and realistic remediation action for existing properties.   Producer Jasmine Gray spoke to Dr. Megan Boston, Senior Lecturer for Civil Engineering, at the University of Waikato about what the new quake-prone building regulations mean for Aotearoa's community safety and heritage.

JCO PO author Dr. Alison M. Schram at Memorial Sloan Kettering Cancer Center shares insights into her JCO PO article, “Retrospective Analysis of BRCA-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors.” Host Dr. Rafeh Naqash and Dr. Schram discuss relevant genomic and clinical features of patients with BRCA-altered uterine sarcoma and the efficacy of PARPis in this population. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO Precision Oncology and associate professor at the OU Health Stephenson Cancer Center. Today, we are excited to be joined by Dr. Alison Schram, Associate Attending Physician and Section Head of Oral Therapeutics with Early Drug Development and Gynecologic Medical Oncology Services at the Memorial Sloan Kettering Cancer Center, and the senior author of the JCO Precision Oncology article titled, "Retrospective Analysis of BRCA-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors." At the time of this recording, our guest's disclosures will be linked in the transcript. Dr. Schram, thank you for joining us today. I am excited to be discussing this very interesting, unique topic based on what you published in JCO PO. Dr. Alison Schram: Thank you for having me. Dr. Rafeh Naqash: What we like to do for these podcasts is try to make them scientifically interesting but at the same time, keep them at a level where our trainees and other community oncology professionals understand the implications of what you've published. So I'd like to start by asking you, what is leiomyosarcoma for those of us who don't necessarily know a lot about leiomyosarcoma, and what are some of the treatment options for these uterine sarcomas? Dr. Alison Schram: Uterine leiomyosarcoma is a rare subtype of uterine cancer, and it represents about 1% of all female cancers in the reproductive tract. This is a rare malignancy that arises from the myometrial lining of the uterus, and it is generally pretty aggressive. In terms of the standard therapy, the standard therapy for uterine leiomyosarcoma includes chemotherapy, generally combination chemotherapy, but despite a few regimens that tend to be effective, the duration of effectiveness is relatively short-lived, and patients with advanced uterine leiomyosarcoma eventually progress and require additional therapy. I will say that localized uterine leiomyosarcoma can be treated with surgery as well. Dr. Rafeh Naqash: Thank you for that description. Now, there are two aspects to what you published. One is the sarcoma aspect, the leiomyosarcoma, and the second is the BRCA mutation. Since we are a precision medicine journal, although we've discussed BRCA a couple of times before, but again, for the sake of our listeners, could you highlight some of the aspects of BRCA and PARP sensitivity for us? Dr. Alison Schram: Yes. So BRCA is a gene that's important for DNA repair, and BRCA mutations can be either inherited as a germline mutation, so one of your parents likely had a BRCA mutation and you inherited one copy. In patients who have an inherited BRCA mutation, the normal cells tend to have one abnormal copy of BRCA, but if a second copy in the cell becomes altered, then that develops into cancer. And so these patients are at increased risk of developing cancers. Specifically, they are at an increased risk of developing ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, and a few others. These cancers are considered BRCA-associated tumors. Alternatively, some patients, more rarely, can develop BRCA-altered cancers completely sporadically. So it's a mutation that happens in the tumor itself, and that can lead to impaired DNA repair and promote cancer progression. And those patients are not, they don't have any inherited risk, but just a random event caused a BRCA mutation in the tumor. The reason this is important is because, in addition to it being potentially important for family members, there are certain treatments that are more effective in BRCA-altered cancers. And the main example is PARP inhibitors, which are small molecule inhibitors that inhibit the PARP enzyme, and there is what we call synthetic lethality. So PARP is important for DNA repair, for single-stranded DNA repair, BRCA is important for double-stranded DNA repair, and in a patient that has a cancer that has a BRCA mutation, that cancer becomes more reliant on single-stranded DNA repair. And if you inhibit it with a PARP inhibitor, the cancer cells are unable to repair DNA, and the cells die. So we call that synthetic lethality. PARP inhibitors are FDA approved in several diseases, predominantly the BRCA-associated diseases I mentioned: breast cancer, ovarian cancer, pancreatic cancer, and prostate cancer. Dr. Rafeh Naqash: That was very beautifully explained. Honestly, I've heard many people explain BRCA before, but you kind of put it in a very simple, easy to understand format. You mentioned this earlier describing germline or hereditary BRCA and somatic BRCA. And from what I gather, you had a predominant population of somatic BRCA, but a couple of germline BRCA as well in your patient population, which we'll go into details as we understand the study. You mentioned the second hit on the germline BRCA that is required for the other copy of the gene to be altered. In your clinical experience, have you seen outside of the study that you published, a difference in the sensitivity of PARP for germline BRCA versus a somatic BRCA that has loss of both alleles? Dr. Alison Schram: So we will get into what's unique about uterine sarcomas in just a minute. In uterine sarcomas, what we have found is that the BRCA mutations tend to be somatic and not germline, as you mentioned. That is in contrast to the other diseases we mentioned, where the vast majority of these tumors are in patients that have germline BRCA alterations. So one thing that's really unique about the uterine sarcoma population and our paper, I believe, is that it is demonstrating an indication for PARP inhibitors in a population that is not characterized by germline BRCA alterations, but truly these by somatic BRCA alterations. If you look at the diseases that PARP inhibitors are validated to be effective in, including the, you know, the ones I mentioned, the BRCA-associated tumors, there's some data in specific context that suggests that perhaps germline alterations are more sensitive to PARP inhibitors, but that's not universal, and it's really tricky to do because the genetic testing that we have doesn't always tell you if you have two hits or just one hit. So you need more complex genetic analysis to truly understand if there is what we call a biallelic loss. And sometimes it's not a second mutation in BRCA. Sometimes it's silencing of the gene by hypermethylation or epigenetics. Some of our clinical trials are now incorporating this data collection to really understand if biallelic loss that we can identify on more complex genetic testing predicts for better outcomes. And we think it's probably true that the patients that have biallelic loss, whether it be germline or somatic biallelic loss, are more likely to benefit from these treatments. That still needs to be tested in a larger cohort of patients prospectively. Dr. Rafeh Naqash: In your clinical experience, I know you predominantly use MSK-IMPACT, but maybe you've perhaps used some other NGS platforms, next-generation sequencing platforms. Have you noticed that these reports for BRCA alterations the report mentioning biallelic loss in certain cases? I personally don't- I do lung cancer, I do early-phase lung cancer as well, but I personally don't actually remember if I've seen a report that actually says biallelic loss. So after this podcast, I'm going to check some of those NGS reports and make sure I look at it. But have you seen it, or what would be a learning point for the listeners there? Dr. Alison Schram: Exactly. And they usually do not. They usually do not explicitly say, “This looks like biallelic loss,” on the reports. The exception would be if there's a deep deletion, then that implies both copies of the gene have been deleted, and so then you can assume that it's a biallelic loss. But oftentimes, when you see a frameshift alteration or a mutation, you don't know whether or not it's a biallelic loss. And you may be able to get some clues based on the variant allele frequencies, but due to things like whole genome duplication or more complex tumor genomics, it's not clear from these reports, and you really do need a more in-depth bioinformatic analysis to understand whether these are biallelic or not. So that is why I suggest that this really needs to be done in the context of a clinical trial, but there is definitely a theoretical rationale for reporting and treating patients with biallelic losses perhaps more so than someone who has a variant of unknown significance that seems to be monoallelic. The other tricky part, as I mentioned, is the fact that there could be epigenetic changes that silence the second copy, so that wouldn't be necessarily evident on a DNA report, and you would need more complex molecular testing to understand that as well. Dr. Rafeh Naqash: Sure. Now, going to your study, could you tell us what prompted the study, what was the patient population that you collected, and how did you go about this research study design? Dr. Alison Schram: It's actually a great story. I was the principal investigator for a clinical trial enrolling patients regardless of their tumor type to a combination of a PARP inhibitor and immunotherapy. And this was a large clinical trial that was being done as a basket study, as I mentioned, for patients that have either germline or somatic alterations with advanced solid tumors that had progressed on standard therapy. And the hypothesis was that the combination of a PARP inhibitor and immunotherapy would be synergistic and that there would be increased efficacy compared to either agent alone and that patients who had BRCA alterations were a sensitive population to test because of their inherent sensitivity to PARP inhibitors and perhaps their increased neoantigen burden from having loss of DNA repair. So this large study, it's been published, really did show that there was efficacy across several tumor types, but it didn't seem to clearly demonstrate synergy between the immunotherapy and the PARP inhibitor as compared to what you might expect from a PARP inhibitor alone, and in addition to a couple of cases, perhaps attributable to the immunotherapy. So maybe additive rather than synergistic efficacy. However, what really struck me looking at the data was that there were three patients with uterine leiomyosarcoma with BRCA deletions who had the best responses of anyone on the study. So incredible, durable responses. One of my patients with a complete response that continues to not have any evidence of cancer eight years after the initiation of this regimen. And for those of us that treat uterine leiomyosarcoma, this is unheard of. These patients generally, as I mentioned, respond, if they do respond to chemotherapy, it's generally short-lived and the cancer progresses. And so a complete response nearly a decade later turns heads in this field. The other interesting thing was that these uterine leiomyosarcoma patients had somatic alterations rather than a germline alteration with a second hit, and the diseases that are best validated for being responsive to PARP inhibitors include the BRCA-associated diseases, the ones that you're at increased risk for if you have a germline BRCA mutation, including breast, pancreas, prostate, and ovarian. And so it was very interesting that this disease type that seemed to be uniquely sensitive to PARP inhibitors with immunotherapy was also different in that patients with uterine leiomyosarcoma don't tend to have a high frequency of BRCA alterations, and in patients that are born with a BRCA alteration, there doesn't seem to be a clearly increased risk of uterine sarcomas. So this population really jumped out as a uniquely sensitive population that differed from the prior indications for PARP inhibitors. Given this patient and these couple of patients that we observed on the combination, in addition to some other case reports and case series that had started to come out in small numbers, we wanted to look back at our large cohort of patients at Memorial Sloan Kettering to see if we could really get a better sense of the numbers. How many patients at Sloan Kettering with uterine sarcomas have BRCA alterations? Are they generally somatic or germline? Are there unique features about these patients in terms of their clinical characteristics? How many of them have received PARP inhibitors, and if so, is this just luck that these three patients did so well, or is this really a good treatment option for patients with BRCA-altered uterine sarcomas? And so we did this retrospective analysis identifying the patients at Sloan Kettering who met these criteria. So in total, we found 35 patients with uterine sarcomas harboring BRCA alterations, and the majority were leiomyosarcoma, about 86% of them had leiomyosarcoma, which is interesting because there are other uterine sarcomas, but it does seem like BRCA alterations tend to be more often in the leiomyosarcomas. And 13 of these patients with uterine leiomyosarcoma were treated with PARP inhibitors in the recurrent or metastatic setting with about half of those patients having an overall response, so that's a significant tumor shrinkage that sustained, and a clinical benefit rate of 62%. And if we look at the patients that had these BRCA2 deep deletions, which was the patient I had that had this amazing response, the overall response rate jumped to 60% and the clinical benefit rate to 80%. And we defined clinical benefit rate as having maintained on the PARP inhibitor without evidence of progression at six months. So this is really impressive for patients with a difficult to treat disease. And we couldn't do a randomized controlled trial comparing it to chemotherapy, but looking retrospectively at outcomes on chemotherapy studies, this was very favorable, particularly because many of these patients were heavily pretreated. So to get a sense of, you know, how this might compare to chemotherapy, we tried to use patients as their own internal controls, and we looked at how long patients were maintained on the PARP inhibitor as compared to how long they were on the treatment just prior. And we used a ratio of 1.3 to say if they were on the PARP inhibitor for 1.3 times what their previous treatment was or longer, that is pretty clearly better, more of a benefit from that regimen. And the majority of patients did meet that bar. So 58% had a PFS ratio greater than 1.3, and the average PFS ratio was 1.9, suggesting, you know, you would expect the the later lines of therapy to actually not work as well, but this suggests that it's actually working better than the immediately prior line of therapy, to me, suggesting that this is truly a good treatment option for these patients. Dr. Rafeh Naqash: Very interesting. And you mentioned that individuals with tumors having deep deletions were probably more responsive. How did you figure out that there was biallelic loss or deep deletions? Was that part of an extended analysis that was done subsequently? Dr. Alison Schram: So the deletions reported on our report, if it's a biallelic deletion, that is the one biallelic molecular alteration that would be reported. So those are, by definition, biallelic, and I think that that may be one of the reasons that's a good biomarker. But also, what's interesting is that if you have both copies deleted of BRCA, you can't develop reversion mutations. So one of the the known mechanisms of resistance to PARP inhibitors in patients who have BRCA alterations are something called a reversion mutation where, if you have a frameshift alteration, for example, in BRCA that makes BRCA protein nonfunctional, you can develop a second mutation that actually puts the DNA back in frame, and a functional protein is now made. And so a mechanism of resistance to PARP inhibitors is actually reverting BRCA to a wild-type protein, and then BRCA's synthetic lethality no longer makes sense and is no longer effective. But if you've deleted both copies of BRCA, you don't have the ability to restore the function, and you can't develop reversion mutations. And that's perhaps why, you know, my patient and others have had these prolonged responses to PARP inhibitors because you don't have the same ability to develop that mechanism of resistance. Dr. Rafeh Naqash: I remember thinking a year and a half back, I had an individual with prostate cancer and with BRCA2, and using liquid biopsy, I had a reversion mutation that we caught. In your practice, have you seen the utility of doing the serial liquid biopsies in these individuals to catch these reversion mutations? Dr. Alison Schram: Yes, absolutely. And in patients that have the ability to develop a reversion mutation, serial cell-free DNA can catch it, but the caveat is that it doesn't always. So if you see an acquired reversion mutation in cell-free DNA, that can be helpful, particularly if you're planning on putting the patient on another line of therapy that might require a dysfunctional BRCA. So if you're putting them on a clinical trial with a PARP combination and the rationale is that they're sensitive because they don't have a functional BRCA, you would want to know if they developed a reversion mutation, and serial cell-free DNA can definitely identify these reversion mutations. Some of the major clinical trials in ovarian cancer have done serial cell-free DNA and have demonstrated the utility of that approach. The caveat is that some of these reversion mutations are not readily caught on cell-free DNA because they're more complex reversion mutations, or they're not, the part of the gene that develops the reversion mutation is not tiled on the panel. And so it doesn't always catch the reversion mutations. Also, depends on the cell-free DNA shedding, depends on the tumor volume and other factors. And we published a related paper of a patient, it was a really interesting case of a patient with prostate cancer who was on a PARP inhibitor and developed what appeared to be a single reversion mutation on one sample, had negative cell-free DNA, single reversion mutation in a tissue biopsy, and then developed disease progression. And we did an autopsy, and the patient kindly consented to an autopsy, and at the time of autopsy, there were 10 unique reversion mutations identified across 11 metastases. So almost each metastasis had a unique reversion mutation, and only one of them had been seen premortem on a tissue biopsy and not on a cell-free DNA. But that autopsy really drove home to me how much we're missing by doing clinical testing in real time and we really don't know the entire genomic complexity of our patients by doing single samples. And theoretically, cell-free DNA can catch DNA from all the metastases, so you might think that that would be a solution, and it definitely can catch reversion mutations that are not seen in a single biopsy, but you really need to do it all. I mean, you need to do the tissue biopsy sampling, you need to do cell-free DNA, and probably one cell-free DNA test is not enough. Dr. Rafeh Naqash: Thank you, again, for that very nice explanation. Now, one quick provocative question. I remember when I was training, the lab that I used to work in, they used to do a lot of phosphorylation markers for DNA damage response, like phospho NBS, RAD51. Have you seen anything of that sort on these biallelic BRCA mutations where tumors are responding, but they also have a very high signature on the phosphorylation side, and it may or may not necessarily correspond to HRD signatures, but have you noticed or done any of that analysis? Dr. Alison Schram: I think that it would be great to do that analysis. And some of the work we're doing now is actually trying to dig a little bit deeper in our cohort of patients to understand are these HRD-positive tumors? Does HRD positivity correlate with response to BRCA alterations? In terms of the functional assays, I would love to be able to do a functional assay in these samples. One of the challenges is that this was a retrospective study and many of the patients were previously treated as standard of care or off-label with these agents, and so we didn't have prospective tissue collection, and so we're really limited by the tissue that was collected as part of standard of care and the consent forms that the patient signed that allow us to do genomic and molecular testing on their samples. So, I think that is hopefully future work that we will do and others will do. Dr. Rafeh Naqash: Sure. Shifting gears to your career trajectory, I'd like to spend a couple of minutes there before we end the podcast. So Dr. Schram, you've obviously been a trailblazer in this space of drug development, early-phase trials. Can you give us a brief synopsis of your journey and how you've successfully done what you're doing and what are some of the things that drive you? Dr. Alison Schram: Well, thank you for saying that. I don't know if that's true, but I'll take the bait. I've been interested in oncology since college and was always very interested in not only the science of oncology but of course, treating patients. And in medical school, I did basic science research in a laboratory and it was very inspiring and made me want to do research in oncology in addition to clinical care. When I became an oncology fellow, I was presented with a very difficult question, which is, “Do you want to be a lab PI and be in the lab, or do you want to do clinical care and clinical research?” And I couldn't choose. I found a mentor who thankfully really had this amazing vision of combining the two and doing very early drug development, taking the data that was being generated by labs and translating it into patients at the earliest stage. So, you know, phase one drug development in molecularly targeted therapies. And so I became very interested as a fellow in early drug development and this ability to translate brand new molecular insights into novel drugs. And I joined the- at Sloan Kettering, there was the Early Drug Development, it was actually a clinic, it was called something different, and it was very fortuitous. My last year of fellowship, the clinic became its own service with the ability to hire staff at Sloan Kettering, and I was the first ever hire to our Early Drug Development Service. And that really inspired me to try and bring these drugs to patients and to really translate the amazing molecular insights that my colleagues here at Sloan Kettering are discovering, and you know, of course, at other institutions and in pharma. And you know, there 's been an amazing revolution in in drug development over the last several years, and I feel very grateful that I've been here for it. You know, I've been able to take the brilliant insights from my colleagues and put these drugs in patients, and I have the amazing privilege of watching patients in many cases that benefit from these treatments. And so I do mostly phase one drug development and molecularly targeted therapies, and truthfully, I am just very fortunate to be around such brilliant people and to have both patients and labs trust me to be able to deliver these new drugs to patients and hopefully develop better drugs that move forward through FDA approval and reach patients across the country. Dr. Rafeh Naqash: Thank you so much. That was very nicely put. And hopefully our trainees and junior faculty find that useful based on their own career trajectories. Thank you, Dr. Schram, for joining us today. Hopefully, we'll see more of your subsequent work in JCO PO. Thank you for giving us all these insights today. Dr. Alison Schram: Thank you for having me. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Dr. Alison Schram Disclosures Consulting or Advisory Role Company: Mersana, Merus NV, Relay Therapeutics, Schrodinger, PMV Pharma ,Blueprint Medicines, Flagship Pioneering, Redona Therapeutics, Repare Therapeutics, Endeavor BioMedicines Research Funding Company: Recipient: Your Institution  Merus, Kura, Surface Oncology, AstraZeneca, Lilly, Pfizer , Black Diamond Therapeutics, BeiGene, Relay Therapeutics, Revolution Medicines,  Repare Therapeutics, PMV Pharma, Elevation Oncology, Boehringer Ingelheim Travel, Accommodations, Expenses Company: PMV Pharma 

China's industrial production maintained its solid growth momentum in July, with value-added output from major industrial enterprises rising 5.7 percent year-on-year and 0.38 percent month-on-month, driven by strong performances in equipment manufacturing and high-tech sectors, which expanded by 8.4 percent and 9.3 percent respectively, official data showed on Friday.周五公布的官方数据显示，中国7月份工业生产保持了强劲增长势头，主要工业企业增加值同比增长5.7%，环比增长0.38%，这得益于装备制造业和高科技行业的强劲表现，分别增长了8.4%和9.3%。 Figures released by the National Bureau of Statistics showed that China's industrial output, which includes manufacturing, mining and utilities, rose 5.7 percent year-on-year in July, following a 6.8 percent increase in June.国家统计局公布的数据显示，继6月份增长6.8%之后，中国7月份包括制造业、采矿业和公用事业在内的工业产出同比增长5.7%。 Retail sales, a key measure of consumer spending, grew 3.7 percent year-on-year in July compared to a 4.8 percent rise in June.零售额是衡量消费者支出的关键指标，7月份同比增长3.7%，而6月份增长4.8%。 Fixed-asset investment rose by 1.6 percent during the January-July period, compared to a 2.8 percent rise in the first half of the previous year.固定资产投资在1月至7月期间增长了1.6%，而去年上半年增长了2.8%。 The surveyed urban unemployment rate stood at 5.2 percent in July, up from 5 percent in June, according to the NBS.根据国家统计局的数据，7月份调查的城市失业率为5.2%，高于6月份的5%。 The NBS highlighted that the data reflects China's steady economic momentum, demonstrating significant resilience and vitality despite the complex and volatile external environment and the adverse impacts of extreme domestic weather conditions.国家统计局强调，这些数据反映了中国稳定的经济势头，尽管面临复杂多变的外部环境和极端国内天气条件的不利影响，但表现出了显著的韧性和活力。 Recognizing that challenges and risks persist in the external environment, the NBS reaffirmed its commitment to promoting the effective implementation of policies aimed at maintaining stability in employment, business activity, markets and expectations.国家统计局认识到外部环境持续存在挑战和风险，重申其致力于促进有效实施旨在维持就业、商业活动、市场和预期稳定的政策。 fixed-assetn.固定资产/ˈfɪkst ˈæsɛt/ external environmentn.外部环境/ɪkˈstɜːnəl ɪnˈvaɪrənmənt/

A State Council executive meeting presided over by Premier Li Qiang on Thursday called for stepping up efforts to improve the effectiveness of macroeconomic policies, while arranging the implementation of interest subsidies on personal consumption loans and loans to service sector businesses to better stimulate consumption and enhance market vitality.本周四，国务院常务会议主持李强总理呼吁加大力度提高宏观经济政策的有效性，同时安排对个人消费贷款和服务业企业贷款实施利息补贴，以更好地刺激消费，增强市场活力。As the country's latest step to boost innovation-driven growth, the State Council executive meeting approved a guideline on deeply implementing the AI Plus initiative, calling for promoting the large-scale, commercial application of artificial intelligence and advancing its accelerated adoption and deep integration across various fields of economic and social development.作为中国推动创新驱动增长的最新举措，国务院常务会议批准了一项关于深入实施人工智能+倡议的指导方针，呼吁促进人工智能的大规模商业应用，并推进其在经济和社会发展各个领域的加速采用和深度融合。On Thursday, the National Bureau of Statistics released the latest purchasing managers index, or PMI, data, which suggested the necessity to consolidate the resilience of the manufacturing sector and overall economic momentum in the second half of the year.周四，国家统计局发布了最新的采购经理人指数（PMI）数据，该数据表明，下半年有必要巩固制造业的韧性和整体经济势头。Economists called for further reinforcing support for domestic demand and employment, as the nation's manufacturing activity cooled in July amid unfavorable weather and the traditional off-season. The official PMI for the manufacturing sector stood at 49.3 in July, down from 49.7 in June, the NBS said on Thursday.经济学家呼吁进一步加强对国内需求和就业的支持，因为在不利天气和传统淡季的影响下，该国7月份的制造业活动有所降温。国家统计局周四表示，7月份制造业官方采购经理人指数为49.3，低于6月份的49.7。Despite the moderation, high-tech manufacturing continued to gain traction in July, highlighting the vitality of the country's industrial upgrading and reinforcing the sector's ability to withstand ongoing external challenges, experts said.专家表示，尽管有所放缓，但高科技制造业在7月份继续获得动力，突显了该国产业升级的活力，并增强了该行业抵御持续外部挑战的能力。Wang Qing, chief macroeconomic analyst at Golden Credit Rating International, said, "With both domestic and external demand softening, the manufacturing PMI ended its two-month rebound and declined within the contraction territory in July."东方金诚首席宏观经济分析师王青表示：“随着国内外需求疲软，制造业采购经理人指数结束了两个月的反弹，7月份在收缩区间内下降。”The official manufacturing PMI has stayed below the 50 mark that separates expansion from contraction for the fourth consecutive month. In July, the subindex of new orders — a barometer of market demand — dropped to 49.4 from 50.2 in June, while that of new export orders went down to 47.1 from 47.7 in the previous month.官方制造业采购经理人指数（PMI）连续第四个月保持在50分以下，50分是扩张与收缩的分界线。7月份，作为市场需求晴雨表的新订单分项指数从6月份的50.2降至49.4，而新出口订单分项指数从前一个月的47.7降至47.1。External headwinds dampened export momentum, while the effect of earlier policies to boost domestic demand started to wane in July, Wang said, adding that high temperatures, heavy rains and flooding in some regions disrupted production.王说，外部逆风抑制了出口势头，而早些时候提振内需的政策的效果在7月份开始减弱，并补充说，一些地区的高温、暴雨和洪水扰乱了生产。Downward pressures on economic growth may intensify in the third quarter, said Wang, who expects additional measures to boost domestic demand as China's relatively low levels of sovereign debt and inflation have offered ample policy room to offset a slowdown in external demand.王表示，第三季度经济增长的下行压力可能会加剧。他预计，随着中国相对较低的主权债务和通胀水平为抵消外部需求放缓提供了充足的政策空间，将采取额外措施提振内需。The Political Bureau of the Communist Party of China Central Committee held a meeting on Wednesday that made arrangements for economic work in the second half, emphasizing that macro policies should continue to exert force and be strengthened at an appropriate time.中共中央政治局周三召开会议，对下半年经济工作作出部署，强调宏观政策要继续发挥作用，适时加强。Xiong Yi, Deutsche Bank's chief economist for China, said, "If GDP growth slows faster than expected, a budget deficit increase may become necessary in the fourth quarter."德意志银行中国首席经济学家熊奕表示：“如果GDP增长放缓速度超过预期，第四季度可能需要增加预算赤字。”He said he anticipates that the Chinese economy will grow 4.8 percent in 2025, following its strong resilience in the first half of the year.他说，他预计中国经济在上半年强劲复苏后，到2025年将增长4.8%。According to Xiong, service consumption is expected to become a new driver of economic growth and employment in the second half of the year. China is enhancing its support for service consumption, with a particular focus on cultural tourism, elderly care, healthcare and domestic services.熊表示，服务消费有望成为下半年经济增长和就业的新动力。中国正在加强对服务消费的支持，特别关注文化旅游、养老、医疗保健和家政服务。Despite the overall decline, the PMI for high-tech manufacturing came in at 50.6 in July, while that for equipment manufacturing was at 50.3, the NBS said, indicating the sectors' capability to thrive despite challenges.国家统计局表示，尽管整体下降，但7月份高科技制造业的采购经理人指数为50.6，而设备制造业的PMI为50.3，表明这些行业在面临挑战的情况下仍有能力蓬勃发展。For instance, Nantong Haixing Electronics Co, an electronic energy storage materials producer based in Nantong, Jiangsu province, saw its export value exceeding 50 million yuan in the first half of 2025, marking a year-on-year increase of 67.23 percent, data from Nanjing Customs showed.例如，南京海关的数据显示，总部位于江苏省南通市的电子储能材料生产商南通海星电子有限公司在2025年上半年的出口额超过5000万元人民币（695万美元），同比增长67.23%。Jin Wenhui, the head of the company's foreign trade unit, said that despite intense worldwide competition, sustained investment in innovation has enabled the company to pursue industrial upgrading and remain resilient in a rapidly evolving global landscape.该公司外贸部门负责人金文辉表示，尽管全球竞争激烈，但对创新的持续投资使该公司能够追求产业升级，并在快速发展的全球格局中保持弹性。Guangdong Greenway Technology Co, a manufacturer of electric motorcycles and bicycles, as well as mobile energy storage systems, based in Dongguan, Guangdong province, shipped its products to more than 80 countries and regions across Europe and the Americas in the first half of the year, according to Huangpu Customs in Guangdong.广东黄埔海关表示，总部位于广东省东莞市的电动摩托车和自行车以及移动储能系统制造商广东绿道科技有限公司上半年将其产品运往欧美80多个国家和地区。Wu Jing, head of the company's foreign trade unit, said, "With years of development in lithium battery manufacturing, we've steadily increased our supply of high-quality, eco-friendly products amid the global shift toward energy transition, while actively exploring new markets and opportunities overseas."该公司外贸部门负责人吴京表示：“随着锂电池制造业多年的发展，在全球能源转型的背景下，我们稳步增加了高质量、环保产品的供应，同时积极探索海外新市场和机遇。”economic momentumn.经济势头/ˌiːkəˈnɒmɪk məˈmɛntəm/budget deficitn.预算赤字/ˈbʌdʒɪt ˈdɛfɪsɪt/

1-2부 [뉴스 신세계] 1. 尹, 4개월만에 내란특검에 재구속…법원 "증거인멸 염려" 2. 해병특검, 국방부·안보실 등 10여곳 압색...'尹 격노설' 조준 3. 이재명 대통령 국정 지지율 65%…윤석열 구속 찬성 71% [NBS] - 헬마우스 임경빈 작가 (출연) [이슈하이킥1] 윤석열 재구속·김건희 특검 수사…정국 전면전 돌입하나 - 신장식 조국혁신당 의원 (출연)

Prezident Peter Pellegrini predniesol svoju prvú správu o stave republiky - vládu pochválil za stavbu nemocníc či opravu ciest a skritizoval za zahraničnú politiku. Povedal, že pri politike na štyri svetové strany sa musíme pozerať najmä na západ.Súd odsúdil guvernéra NBS a bývalého ministra financií za Smer Petra Kažimíra za korupciu.A skupina zahraničných europoslancov prišla na Slovensko debatovať aj o využívaní, respektíve zneužívaní, eurofondov - od Matúša Šutaja Eštoka si vypočuli, že sú trestnou výpravou a Andrej Danko zašiel ešte ďalej, keď jedného z nich nazval českým slovom “vůl”.Rovnako nevkusne sa vyjadrovali slovenskí politici aj o nemeckom kancelárovi Friedrichovi Merzovi, ktorý hrozí Slovensku zablokovaním eurofondov.Premiér Fico odkazuje, že nie je malý žiačik, ktorého treba poučovať. Pobočka Smeru nazvala Merza "führerom". A máme tu aj ďalšie vyjadrenie o vystúpení z EÚ - tentokrát s tým prišiel šéf SNS Danko.Sobotným Dobrým ránom vás sprevádzajú Zuzana Kovačič Hanzelová a Jakub Filo.Otázky do nasledujúcej epizódy Dobrého rána sobota nám zasielajte na e-mail dobrerano@sme.sk, ideálne vo forme hlasovej správy. Do predmetu napíšte Otázka do sobotného Dobrého rána.Zdroje zvukov: TA3, Denník N, Facebook/Robert Fica, Matúš Šutaj Eštok, Telegram/Lukáš Machala–Všetky podcasty denníka SME nájdete na⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ sme.sk/podcasty⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠–Odoberajte aj audio verziu denného newslettra⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ SME.sk⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ s najdôležitejšími správami na⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ sme.sk/brifing⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Business-as-usual this morning as TDS sufferers freak about the President, his interview w/ NBS's Kristen Welker being the chief trigger. And then there's that little thing about the Pope.

YiFan Li comes on to talk about the strength we've seen in GDT/SGX prices and NBS data suggesting milk production in China was up 1.7% during the first quarter.

There are two state conventions going on the through the weekend of April 5 where young adults are preparing and competing for their futures. Click on the podcast to learn more about what drives Montana’s young adults, as NBS’s Joe […] The post Young Adults Prepping, Competing for Their Futures first appeared on Voices of Montana.

This week on The Sneaker Podcast, the squad thinks of breaking out all their NBs, we find out what hunter-killer might be about, and we go back and remember the last time particular sneaker situations happened to us! Time to turn back time! Time to turn it up!   The sponsors: Our favorite streetwear https://kuwallatee.com/ Our favorite hat shop https://www.styll.ca/   Instagram: https://www.instagram.com/thesneakerpodcast/   The Crew: https://www.instagram.com/misterqmart/ https://www.instagram.com/justkalby/ https://www.instagram.com/po.tato/ https://www.instagram.com/christopher.chiu/   YouTube: https://www.youtube.com/c/TheSneakerPodcast   Twitter: https://twitter.com/thesneakerpod   Facebook: https://www.facebook.com/thesneakerpodcast/   #TheSneakerPodcast

[뉴스 연구소] 尹 체포적부심 기각/ 내란특검 합의될까?/ 이스라엘-하마스 전쟁 종식- 경향신문 박순봉 기자, 김준일 시사 평론가 [인터뷰 (1)] 조사 거부하는 尹/ 조기 대선 국면 전환?/ 민주 ‘내란특검’ 국힘 ‘비상계엄특검’- 국민의힘 안철수 의원 [놓지마 뉴스]- 방송인 강승희 [뉴스 게임] 尹의 악수? 수사 비협조·체포적부심 신청/ NBS 국힘 35% vs 민주 33%?- 최재성 前 정무수석- 국민의힘 김성태 前 원내대표 [탐정 손수호] 尹의 법기술: 체포적부심·서부지방법원·조사 거부·구속영장- 법무법인 ‘지혁’ 손수호 변호사 (법학 박사) [미니 댓꿀쇼] 탄핵 심판 결과 예상/ 포고령 1호 엇갈린 주장- 법무법인 ‘지혁’ 손수호 변호사 (법학 박사)See omnystudio.com/listener for privacy information.